NKGN Insider Trading Activity and SEC Form 4 Filings
NKGN insider trading summary
No open-market insider purchases or sales of NKGen Biotech, Inc. (NKGN) have been reported on SEC Form 4 in the past 12 months.
Latest NKGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 27, 2025 | Andrew Jin-Chan Cherng | 10% Owner | Buy | $2.5M (19,669,552 @ $0.13) |
| May 27, 2025 | Peggy Cherng | 10% Owner | Buy | $2.5M (19,669,552 @ $0.13) |
| May 27, 2025 | CFIC-2015 NV Family Investments, LLC | 10% Owner | Buy | $2.5M (19,669,552 @ $0.13) |
| May 5, 2025 | Paul Y. Song | Chief Executive Officer | Buy | $2.7M (20,849,725 @ $0.13) |
| Dec 7, 2023 | Paul Y. Song | Chief Executive Officer | Buy | $250 (76.06 @ $3.29) |
| Dec 6, 2023 | Paul Y. Song | Chief Executive Officer | Buy | $250 (75.3 @ $3.32) |
| Dec 5, 2023 | Paul Y. Song | Chief Executive Officer | Buy | $350 (105.17 @ $3.33) |
| Dec 4, 2023 | Paul Y. Song | Chief Executive Officer | Buy | $500 (162.78 @ $3.07) |
| Dec 4, 2023 | James A Graf | Interim CFO | Buy | $1K (450 @ $3.19) |
| Dec 4, 2023 | Graf Acquisition Partners IV LLC | 10% Owner | Buy | $1K (450 @ $3.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.